Cargando…

Galcanezumab modulates Capsaicin-induced C-fiber reactivity

BACKGROUND: The vasodilatory calcitonin-gene related peptide (CGRP) is understood as pivotal mediator in migraine pathophysiology. Blocking CGRP with small molecules or monoclonal antibodies (CGRP-mAb) reduces migraine frequency. However, prescription of CGRP-mAbs is still regulated and possible pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basedau, Hauke, Oppermann, Thalea, Gundelwein Silva, Elisa, Peng, Kuan-Po, May, Arne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638712/ https://www.ncbi.nlm.nih.gov/pubmed/35796521 http://dx.doi.org/10.1177/03331024221112906

Ejemplares similares

High-Density Electroencephalography-Informed Multiband Functional Magnetic Resonance Imaging Reveals Rhythm-Specific Activations Within the Trigeminal Nociceptive Network
por: Basedau, Hauke, et al.
Publicado: (2022)

Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
por: Basedau, Hauke, et al.
Publicado: (2022)

Galcanezumab for migraine
Publicado: (2020)

Galcanezumab-induced fixed drug eruption
por: Klager, Skylar, et al.
Publicado: (2021)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

The Role of Capsaicin-induced Acute Inactivation of C-fibers on Tactile Learning in Rat
por: Rahmani, Mohammadreza, et al.
Publicado: (2013)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

The usefulness of C-reactive protein in predicting malaria parasitemia in a sub-Saharan African region
por: Sarfo, Bismark Osei, et al.
Publicado: (2018)

Role of capsaicin-sensitive C-fiber afferents in neuropathic pain-induced synaptic potentiation in the nociceptive amygdala
por: Nakao, Ayano, et al.
Publicado: (2012)

C-fiber-related EEG-oscillations induced by laser radiant heat stimulation of capsaicin-treated skin
por: Domnick, Claudia, et al.
Publicado: (2009)

Capsaicin-Induced Skin Desensitization Differentially Affects A-Delta and C-Fiber-Mediated Heat Sensitivity
por: van Neerven, Sabien G. A., et al.
Publicado: (2020)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
por: Yalinay Dikmen, Pınar, et al.
Publicado: (2023)

Reactivation of mutant p53 by capsaicin, the major constituent of peppers
por: Garufi, Alessia, et al.
Publicado: (2016)

The Involvement of Endothelin Pathway in Chronic Psychological Stress-Induced Bladder Hyperalgesia Through Capsaicin-Sensitive C-Fiber Afferents
por: Qin, Chuying, et al.
Publicado: (2022)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Reactive metabolites of acetaminophen activate and sensitize the capsaicin receptor TRPV1
por: Eberhardt, Mirjam J., et al.
Publicado: (2017)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
por: Detke, Holland C., et al.
Publicado: (2018)

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
por: Rosen, Noah, et al.
Publicado: (2019)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
por: Mo, Heejung, et al.
Publicado: (2022)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Occupational Rhinitis Induced by Capsaicin
por: Nam, Young-Hee, et al.
Publicado: (2012)

Redefining migraine phases – a suggestion based on clinical, physiological, and functional imaging evidence
por: Peng, Kuan-Po, et al.
Publicado: (2020)

Ca(2+)/Calmodulin Modulates TRPV1 Activation by Capsaicin
por: Rosenbaum, Tamara, et al.
Publicado: (2004)

Capsaicin as an amphipathic modulator of Na(V)1.5 mechanosensitivity
por: Cowan, Luke M., et al.
Publicado: (2022)

Analysis of the Ability of Capsaicin to Modulate the Human Gut Microbiota In Vitro
por: Mahalak, Karley K., et al.
Publicado: (2022)

Capsaicin 8% patch reversibly reduces A-delta fiber evoked potential amplitudes
por: Papagianni, Aikaterini, et al.
Publicado: (2018)

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
por: Gklinos, Panagiotis, et al.
Publicado: (2020)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
por: Schwedt, Todd J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_denh0ldnc22ml3f5b95vocs83i